151 related articles for article (PubMed ID: 35105709)
1. Anakinra in Patients With Systemic Juvenile Idiopathic Arthritis: Long-term Safety From the Pharmachild Registry.
Giancane G; Papa R; Vastert S; Bagnasco F; Swart JF; Quartier P; Antón J; Kamphuis S; Sanner H; Glerup M; De Benedetti F; Tsitsami E; Remesal A; Moreno E; De Inocencio J; Myrup C; Pallotti C; Koné-Paut I; Franck-Larsson K; Malmström H; Cederholm S; Pistorio A; Wulffraat N; Ruperto N;
J Rheumatol; 2022 Apr; 49(4):398-407. PubMed ID: 35105709
[TBL] [Abstract][Full Text] [Related]
2. Long-term surveillance of biologic therapies in systemic-onset juvenile idiopathic arthritis: data from the German BIKER registry.
Klein A; Klotsche J; Hügle B; Minden K; Hospach A; Weller-Heinemann F; Schwarz T; Dressler F; Trauzeddel R; Hufnagel M; Foeldvari I; Borte M; Kuemmerle-Deschner J; Brunner J; Oommen PT; Föll D; Tenbrock K; Urban A; Horneff G
Rheumatology (Oxford); 2020 Sep; 59(9):2287-2298. PubMed ID: 31846042
[TBL] [Abstract][Full Text] [Related]
3. Safety and efficacy of anakinra as first-line or second-line therapy for systemic onset juvenile idiopathic arthritis - data from the German BIKER registry.
Atemnkeng Ntam V; Klein A; Horneff G
Expert Opin Drug Saf; 2021 Jan; 20(1):93-100. PubMed ID: 33148061
[No Abstract] [Full Text] [Related]
4. Experience with etanercept, tocilizumab and interleukin-1 inhibitors in systemic onset juvenile idiopathic arthritis patients from the BIKER registry.
Horneff G; Schulz AC; Klotsche J; Hospach A; Minden K; Foeldvari I; Trauzeddel R; Ganser G; Weller-Heinemann F; Haas JP
Arthritis Res Ther; 2017 Nov; 19(1):256. PubMed ID: 29166924
[TBL] [Abstract][Full Text] [Related]
5. Pharmacovigilance in juvenile idiopathic arthritis patients treated with biologic or synthetic drugs: combined data of more than 15,000 patients from Pharmachild and national registries.
Swart J; Giancane G; Horneff G; Magnusson B; Hofer M; Alexeeva Е; Panaviene V; Bader-Meunier B; Anton J; Nielsen S; De Benedetti F; Kamphuis S; Staņēviča V; Tracahana M; Ailioaie LM; Tsitsami E; Klein A; Minden K; Foeldvari I; Haas JP; Klotsche J; Horne AC; Consolaro A; Bovis F; Bagnasco F; Pistorio A; Martini A; Wulffraat N; Ruperto N;
Arthritis Res Ther; 2018 Dec; 20(1):285. PubMed ID: 30587248
[TBL] [Abstract][Full Text] [Related]
6. A multicentre, randomised, double-blind, placebo-controlled trial with the interleukin-1 receptor antagonist anakinra in patients with systemic-onset juvenile idiopathic arthritis (ANAJIS trial).
Quartier P; Allantaz F; Cimaz R; Pillet P; Messiaen C; Bardin C; Bossuyt X; Boutten A; Bienvenu J; Duquesne A; Richer O; Chaussabel D; Mogenet A; Banchereau J; Treluyer JM; Landais P; Pascual V
Ann Rheum Dis; 2011 May; 70(5):747-54. PubMed ID: 21173013
[TBL] [Abstract][Full Text] [Related]
7. Anakinra treatment in macrophage activation syndrome: a single center experience and systemic review of literature.
Sönmez HE; Demir S; Bilginer Y; Özen S
Clin Rheumatol; 2018 Dec; 37(12):3329-3335. PubMed ID: 29663156
[TBL] [Abstract][Full Text] [Related]
8. Anaphylaxis to anakinra in a pediatric patient with systemic juvenile idiopathic arthritis successfully treated with canakinumab: a case-based review.
Aguiar CL; Pan N; Adams A; Barinstein L; Lehman TJ
Clin Rheumatol; 2015 Oct; 34(10):1821-4. PubMed ID: 25697878
[TBL] [Abstract][Full Text] [Related]
9. Long-term safety profile of anakinra in patients with severe cryopyrin-associated periodic syndromes.
Kullenberg T; Löfqvist M; Leinonen M; Goldbach-Mansky R; Olivecrona H
Rheumatology (Oxford); 2016 Aug; 55(8):1499-506. PubMed ID: 27143789
[TBL] [Abstract][Full Text] [Related]
10. Systemic onset juvenile idiopathic arthritis: a single center experience.
Sağ E; Uzunoğlu B; Bal F; Sönmez HE; Demir S; Bilginer Y; Özen S
Turk J Pediatr; 2019; 61(6):852-858. PubMed ID: 32134578
[TBL] [Abstract][Full Text] [Related]
11. Tocilizumab in systemic juvenile idiopathic arthritis in a real-world clinical setting: results from 1 year of postmarketing surveillance follow-up of 417 patients in Japan.
Yokota S; Itoh Y; Morio T; Origasa H; Sumitomo N; Tomobe M; Tanaka K; Minota S
Ann Rheum Dis; 2016 Sep; 75(9):1654-60. PubMed ID: 26644233
[TBL] [Abstract][Full Text] [Related]
12. Anakinra in Systemic Juvenile Idiopathic Arthritis: A Single-center Experience.
Pardeo M; Pires Marafon D; Insalaco A; Bracaglia C; Nicolai R; Messia V; De Benedetti F
J Rheumatol; 2015 Aug; 42(8):1523-7. PubMed ID: 26034148
[TBL] [Abstract][Full Text] [Related]
13. Adalimumab versus adalimumab and methotrexate for the treatment of juvenile idiopathic arthritis: long-term data from the German BIKER registry.
Klein A; Becker I; Minden K; Foeldvari I; Haas JP; Horneff G
Scand J Rheumatol; 2019 Mar; 48(2):95-104. PubMed ID: 30411654
[TBL] [Abstract][Full Text] [Related]
14. Safety and efficacy of etanercept in children with juvenile idiopathic arthritis below the age of 2 years.
Windschall D; Müller T; Becker I; Horneff G
Rheumatol Int; 2015 Apr; 35(4):613-8. PubMed ID: 25208527
[TBL] [Abstract][Full Text] [Related]
15. Anakinra for systemic juvenile arthritis: the Rocky Mountain experience.
Zeft A; Hollister R; LaFleur B; Sampath P; Soep J; McNally B; Kunkel G; Schlesinger M; Bohnsack J
J Clin Rheumatol; 2009 Jun; 15(4):161-4. PubMed ID: 19363453
[TBL] [Abstract][Full Text] [Related]
16. Experiences with IL-1 blockade in systemic juvenile idiopathic arthritis - data from the German AID-registry.
Lainka E; Baehr M; Raszka B; Haas JP; Hügle B; Fischer N; Foell D; Hinze C; Weissbarth-Riedel E; Kallinich T; Horneff G; Windschall D; Lilienthal E; Niehues T; Neudorf U; Berendes R; Küster RM; Oommen PT; Rietschel C; Lutz T; Weller-Heinemann F; Tenbrock K; Heubner GL; Klotsche J; Wittkowski H
Pediatr Rheumatol Online J; 2021 Mar; 19(1):38. PubMed ID: 33752669
[TBL] [Abstract][Full Text] [Related]
17. Anakinra and hepatotoxicity in pediatric rheumatology: a case series.
Martins FR; Azevedo AC; Ganhão S; Aguiar F; Rodrigues M; Brito I
Pediatr Rheumatol Online J; 2023 Oct; 21(1):112. PubMed ID: 37803456
[TBL] [Abstract][Full Text] [Related]
18. Anakinra: a safe and effective first-line treatment in systemic onset juvenile idiopathic arthritis (SoJIA).
Hedrich CM; Bruck N; Fiebig B; Gahr M
Rheumatol Int; 2012 Nov; 32(11):3525-30. PubMed ID: 22083619
[TBL] [Abstract][Full Text] [Related]
19. Predictors of Effectiveness of Anakinra in Systemic Juvenile Idiopathic Arthritis.
Saccomanno B; Tibaldi J; Minoia F; Bagnasco F; Pistorio A; Guariento A; Caorsi R; Consolaro A; Gattorno M; Ravelli A
J Rheumatol; 2019 Apr; 46(4):416-421. PubMed ID: 30647180
[TBL] [Abstract][Full Text] [Related]
20. The efficacy and safety of interleukin-1-receptor antagonist anakinra in the treatment of systemic juvenile idiopathic arthritis.
Swart JF; Barug D; Möhlmann M; Wulffraat NM
Expert Opin Biol Ther; 2010 Dec; 10(12):1743-52. PubMed ID: 20979564
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]